Achieving the 95 95 95 targets for all: A pathway to ending AIDS

Frescura, Luisa; Godfrey‐Faussett, Peter; A., Ali Feizzadeh; El‐Sadr, Wafaa; Syarif, Omar; Ghys, Peter D.

doi:10.1371/journal.pone.0272405

Cited by 171 publications

(140 citation statements)

References 20 publications

Supporting

Mentioning

105

Contrasting

Order By: Relevance

“…The UNAIDS 2020 “90-90-90” target has been a driving force behind the scale-up of effective HIV treatment, thus reducing onward transmission of HIV [ 18 ]. The implementation of HIV treatment services needs to address all the complexity of the diversity of the 37.7 million people estimated to be living with HIV in 2020 [ 19 ]. However, the success of the 90-90-90 treatment target arises both from the immediacy of saving lives by treating people living with HIV but also from the conceptual simplicity that every one of the 37.7 million people living with HIV needs to be diagnosed and linked to highly effective treatment.…”

Section: Accomplishments Of Hiv Prevention To Date and Remaining Chal...mentioning

confidence: 99%

HIV prevention for the next decade: Appropriate, person-centred, prioritised, effective, combination prevention

et al. 2022

Self Cite

View full text Add to dashboard Cite

UNAIDS and a broad range of partners have collaborated to establish a new set of HIV prevention targets to be achieved by 2025 as an intermediate step towards the sustainable development target for 2030. The number of new HIV infections in the world continues to decline, in part due to the extraordinary expansion of effective HIV treatment. However, the decline is geographically heterogeneous, with some regions reporting a rise in incidence. The incidence target that was agreed for 2020 has been missed. A range of exciting new HIV prevention technologies have become available or are in the pipeline but will only have an impact if they are accessible and affordable and delivered within systems that take full account of the social and political context in which most infections occur. Most new infections occur in populations that are marginalised or discriminated against due to structural, legal, and cultural barriers. The new targets imply a new approach to HIV prevention that emphasises appropriate, person-centred, prioritised, effective, combination HIV prevention within a framework that reduces existing barriers to services and acknowledges heterogeneity, autonomy, and choice. These targets have consequences for people working in HIV programmes both for delivery and for monitoring and evaluation, for health planners setting local and national priorities, and for funders both domestic and global. Most importantly, they have consequences for people who are at risk of HIV exposure and infection. Achieving these targets will have a huge impact on the future of the HIV epidemic and put us back on track towards ending AIDS as a public health threat by 2030.

show abstract

Section: Accomplishments Of Hiv Prevention To Date and Remaining Chal...mentioning

confidence: 99%

HIV prevention for the next decade: Appropriate, person-centred, prioritised, effective, combination prevention

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…In 2020, the Joint United Nations Program on HIV/AIDS launched another ambitious 95‐95‐95 project to be achieved by 2030 163 . Nevertheless, despite these efforts and substantial improvements, numerous countries are still far from meeting the current target of the Joint United Nations Program on HIV/AIDS 162,164 . Moreover, although the first clinical trial of an HIV vaccine candidate was launched in 1987, and over $16 billion was spent on vaccine research and development between 2000 and 2020, 165,166 no preventative vaccine against HIV has been approved by the end of 2022.…”

Section: Clinical Progress Of Mrna Candidates Beyond Covid‐19mentioning

confidence: 99%

mRNA vaccines: The future of prevention of viral infections?

Rzymski

Szuster‐Ciesielska

Dzieciątkowski

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Messenger RNA (mRNA) vaccines against COVID-19 are the first authorized biological preparations developed using this platform. During the pandemic, their administration has been proven to be a life-saving intervention. Here, we review the main advantages of using mRNA vaccines, identify further technological challenges to be met during the development of the mRNA platform, and provide an update on the clinical progress on leading mRNA vaccine candidates against different viruses that include influenza viruses, human immunodeficiency virus 1, respiratory syncytial virus, Nipah virus, Zika virus, human cytomegalovirus, and Epstein-Barr virus. The prospects and challenges of manufacturing mRNA vaccines in low-income countries are also discussed. The ongoing interest and research in mRNA technology are likely to overcome some existing challenges for this technology (e.g., related to storage conditions and immunogenicity of some components of lipid nanoparticles) and enhance the portfolio of vaccines against diseases for which classical formulations are already authorized. It may also open novel pathways of protection against infections and their consequences for which no safe and efficient immunization methods are currently available.

show abstract

“…The UNAIDS targets for 2025, which were amended in December 2020, called for 95 percent of individuals living with HIV to know their status, 95 percent of those who knew their status to be on treatment, and 95 percent of those on treatment to have viral suppression [70][71]. The HIV targets (cascade) has increasingly been used to direct and assess programmes to improve population antiretroviral treatment (ART) coverage, a vital element of treatment prevention strategy [72].…”

Section: Effect Of Covid-19 On Unaids Targetsmentioning

confidence: 99%

A Review of the Efforts Made by Several African Countries to Reach UNAIDS Targets and the Effects of the Covid-19 on People Living with HIV

Willie¹

2022

JQHE

View full text Add to dashboard Cite

Even though COVID-19 has spread faster than any other health problem in the last 100 years, it is not the first pandemic that the modern world has had to deal with. As countries try to deal with the COVID-19 pandemic, which is getting worse and worse, they are already using what they have learnt and invested in while dealing with HIV by putting systems to use, and figuring out what dynamic changes are needed to build a new way forward towards health systems that are optimally effective, accountable, inclusive, fair, and well-resourced, with services that are accessible, integrated, tailored, and people-centred. The COVID-19 pandemic has had a lot of terrible effects on people, communities, and societies all over the world. People with long-term health problems may be more likely to get COVID-19 or have complications from it. People who get the virus can get sick or die, and the physical distance needed to flatten the curve of new cases is hurting the economy. This hurts the economy in ways that affect mental health and other health problems, which particularly hurts marginalised communities. COVID-19 is affecting people with HIV (PWH) in unique ways, and it will continue to influence HIV research and treatment after the COVID-19 crisis is over. This is because HIV affects marginalised communities more than other groups.

show abstract

Achieving the 95 95 95 targets for all: A pathway to ending AIDS

Cited by 171 publications

References 20 publications

HIV prevention for the next decade: Appropriate, person-centred, prioritised, effective, combination prevention

HIV prevention for the next decade: Appropriate, person-centred, prioritised, effective, combination prevention

mRNA vaccines: The future of prevention of viral infections?

A Review of the Efforts Made by Several African Countries to Reach UNAIDS Targets and the Effects of the Covid-19 on People Living with HIV

Contact Info

Product

Resources

About